A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 910-917

  Narisawa Saito, Mako ^a   Inagawa, Yuki ^a   Yoshimatsu, Yuki ^a   Haga, Kei ^a   Tanaka, Katsuyuki ^a   Egawa, Nagayasu ^a   Ohno, Shin Ichi ^a   Ichikawa, Hitoshi ^a   Yugawa, Takashi ^a   Fujita, Masatoshi ^a,b   Kiyono, Tohru ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETICS; FEMALE; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TONGUE; TUMOR GROWTH; UTERINE CERVIX; VIRUS ONCOGENE;

EID: 84859570193     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs104     Document Type: Article

References (37)

1. Walboomers, J. M. et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189, 12-19.
2. zur Hausen, H. (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer, 2, 342-350.
3. Klaes, R. et al. (1999) Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res., 59, 6132-6136.
4. Narisawa-Saito, M. et al. (2008) An in vitro multistep carcinogenesis model for human cervical cancer. Cancer Res., 68, 5699-5705.
5. Sasaki, R. et al. (2009) Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis, 30, 423-431.
6. Soucek, L. et al. (2002) Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res., 62, 3507-3510.
7. Carey, B. W. et al. (2009) Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl Acad. Sci. USA, 106, 157-162.
8. Handa, K. et al. (2007) E6AP-dependent degradation of DLG4/PSD95 by high-risk human papillomavirus type 18 E6 protein. J. Virol., 81, 1379-1389.
9. Yada, M. et al. (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J., 23, 2116-2125.
10. Brunet, A. et al. (1994) Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene, 9, 3379-3387.
11. Pages, G. et al. (1994) Constitutive mutant and putative regulatory serine phosphorylation site of mammalian MAP kinase kinase (MEK1). EMBO J., 13, 3003-3010.
12. Cosgrave, N. et al. (2006) Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J. Mol. Endocrinol., 37, 377-390.
13. Balakumaran, B. S. et al. (2009) MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4Ebinding protein 1-mediated inhibition of autophagy. Cancer Res., 69, 7803-7810.
14. Schmidt, E. V. et al. (2009) Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle, 8, 1344-1351.
15. Watnick, R. S. et al. (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell, 3, 219-231.
16. Chang, D. W. et al. (2000) The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol. Cell. Biol., 20, 4309-4319.
17. Meyer, N. et al. (2008) Reflecting on 25 years with MYC. Nat. Rev. Cancer, 8, 976-990.
18. Eberhardy, S. R. et al. (2000) Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation. J. Biol. Chem., 275, 33798-33805.
19. Yugawa, T. et al. (2007) Regulation of Notch1 gene expression by p53 in epithelial cells. Mol. Cell. Biol., 27, 3732-3742.
20. Veldman, T. et al. (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl Acad. Sci. USA, 100, 8211-8216.
21. Soucek, L. et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature, 455, 679-683.
22. Peter, M. et al. (2006) MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene, 25, 5985-5993.
23. Wang, X. et al. (2011) Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res., 71, 925-936.
24. Hydbring, P. et al. (2010) Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc. Natl Acad. Sci. USA, 107, 58-63.
25. Tan, J. et al. (2010) B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell, 18, 459-471.
26. Bowden, P. E. et al. (1992) Down-regulation of keratin 14 gene expression after v-Ha-ras transfection of human papillomavirus-immortalized human cervical epithelial cells. Cancer Res., 52, 5865-5871.
27. DiPaolo, J. A. et al. (1989) Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras. Oncogene, 4, 395-399.
28. Durst, M. et al. (1989) Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology, 173, 767-771.
29. Hodivala, K. J. et al. (1994) Integrin expression and function in HPV 16-immortalised human keratinocytes in the presence or absence of v-Ha-ras. Comparison with cervical intraepithelial neoplasia. Oncogene, 9, 943-948.
30. Zushi, Y. et al. (2011) An in vitro multistep carcinogenesis model for both HPV-positive and -negative human oral squamous cell carcinomas. Am. J. Cancer Res., 1, 869-881.
31. Li, F. et al. (2010) Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers. Am. J. Pathol., 176, 1629-1638.
32. Smith, K. N. et al. (2010) Myc represses primitive endoderm differentiation in pluripotent stem cells. Cell Stem Cell, 7, 343-354.
33. Murphy, D. J. et al. (2008) Distinct thresholds govern Myc's biological output in vivo. Cancer Cell, 14, 447-457.
34. Takahashi, K. et al. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-676.
35. Kim, J. et al. (2010) Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell, 143, 313-324.
36. Vita, M. et al. (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol., 16, 318-330.
37. Shi, J. et al. (2009) Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg. Med. Chem. Lett., 19, 6038-6041.